A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Clinical trial NCT06681922 · RECRUITING
Trial details
- NCT number
- NCT06681922
- Sponsor
- Northwell Health
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-23
- Primary completion
- 2027-10-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.